MinireviewPharmacokinetic Considerations in Obesity
References and Notes (95)
Mortality and weight: Insured lives and the Americal Cancer Society studies
Ann. Intern. Med.
(1985)Medical hazards of obesity
Ann. Intern. Med.
(1993)- et al.
Body size and breast cancer prognosis: a statistical explanation of the discrepancies
Cancer Res.
(1989) - et al.
Obesity at diagnosis of breast carcinoma influences duration of disease‐free survival
Ann. Intern. Med.
(1992) - et al.
Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer
Ann. Intern. Med.
(1994) Clinical pharmacokinetics of drugs in obesity: an update
Clin Pharmacokinet.
(1993)- et al.
Special pharmacokinetic considerations in the obese
Drug pharmacokinetics in the obese
Fundam. Clin. Pharmacol.
(1988)- et al.
Influence of obesity on drug disposition
Clin. Pharmacy
(1987) - et al.
Drug disposition in obese humans: an update
Clin. Pharmacokinet.
(1986)
Alterations in drug distribution and clearance due to obesity
J Pharmacol. Exp. Ther.
(1981)
Pharmacokinetic characteristics of the obese overfed rat model
Int. J. Obes.
(1989)
Effect of age, gender, and obesity on midazolam kinetics
Anesthesiology
(1984)
A comparison of the pharmacokinetics of propanolol in obese and normal volunteers
Br. J. Clin. Pharmacol.
(1986)
The impact of body weight on cyclosporine pharmacokinetics in renal transplant recipients
Transplantation
(1989)
The pharmacokinetics of dexfenfluramine in obese and nonobese subjects
Br. J. Clin. Pharmacol.
(1995)
Clinical Pharmacokinetics: Concepts and Applications
(1989)
Serum alpha1‐acid glycoprotein and the binding of drugs in obesity
Br. J. Clin. Pharmacol.
(1983)
Serum protein binding and the role of increased alpha1‐acid glycoprotein in moderately obese male subjects
Br. J. Clin. Pharmacol.
(1984)
Body composition in obesity
Acta Med. Scand.
(1970)
The sizes and numbers of cells in visceral organs in human obesity
Am. J. Clin. Pathol.
(1970)
The relation of the weight of the heart to the weight of the body and of the weight of the heart to age
Am. Heart J.
(1928)
Blood volume, cardiac output, and disposition of systemic blood flow in extreme obesity
Cardiovasc. Res. Cent. Bull.
(1962)
Obesity and cardiac performance
Am. J. Cardiol.
(1964)
Obesity and cardiac function
Circulation
(1981)
Effect of obesity on CSA disposition
Transplantation
(1988)
Thiopental disposition in lean and obese patients undergoing surgery
Anesthesiology
(1982)
Prolonged accumulation of diazepam in obesity
J Clin Pharmacol
(1983)
Partition coefficients and their uses
Chem. Rev.
(1971)
Predicting in vivo benzodiazepine distribution based upon in vitro lipophilicity
Clin. Pharmacol. Ther.
(1982)
Digoxin disposition in obesity: clinical pharmacokinetic investigation
Am. Heart J.
(1981)
Procainimide disposition in obesity
Drug Intell. Clin. Pharm.
(1983)
Prediction of apparent volumes of distribution in obesity
Methods Find Exp Clin Pharmacol
(1986)
The distribution and concentration of tritiated digoxin in human tissues
Ann. Intern. Med.
(1967)
The effect of obesity on apparent volume of distribution of theophylline
Pediatr. Pharmacol.
(1982)
Theophylline disposition in obesity
Clin. Pharmacol. Ther.
(1978)
Effect of body weight on the volume of distribution of theophylline
Lung
(1988)
A controlled investigation of the pharmacokinetics of gentamicin and tobramycin in obese subjects
J Infect. Dis
(1978)
Tobramycin pharmacokinetics in morbidly obese patients
Clin. Pharmacol. Ther.
(1979)
Amikacin pharmacokinetics in morbidly obese patients
Am. J. Hosp. Pharm.
(1980)
Influence of extreme obesity on the body disposition and neuromuscular blocking effect of atracurium
Clin. Pharmacol. Ther.
(1990)
Pharmacokinetics of intravenous bisoprolol in obese and nonobese volunteers
Eur. J. Clin. Pharmacol.
(1991)
Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects
Eur. J. Clin. Pharmacol.
(1997)
Phenytoin disposition in obesity
Arch. Neurol.
(1985)
Comparative pharmacokinetics of intravenous propanolol in obese and normal volunteers
J. Clin. Pharmacol.
(1987)
Pharmacokinetics and pharmaco‐dynamics of triazolam after two intermittent doses in obese and normal‐weight men
J. Clin. Psychopharmacol.
(1995)
Verapamil pharmacodynamics and disposition in obese hypertensives
J. Cardiovasc. Pharmacol.
(1988)
Cited by (174)
Obesity and impact on gastroesophageal reflux disease
2022, Obesity and Esophageal DisordersDifferential effect of body mass index (BMI) on outcomes of patients treated with docetaxel in prostate cancer - An exploratory analysis.
2022, Cancer Treatment and Research CommunicationsCitation Excerpt :The relationship between obesity and cancer is rather [3]. Apart from being a risk factor for cancers, obesity can also alter anticancer drug metabolism, especially that of lipophilic drugs [4,5]. However, there is sparse literature on drug efficacy as a function of adiposity, despite a significant proportion of cancer patients being overweight or obese.
Effect of obesity on gastrointestinal transit, pressure and pH using a wireless motility capsule
2021, European Journal of Pharmaceutics and BiopharmaceuticsThe Crashing Obese Patient
2020, Emergency Medicine Clinics of North America
Copyright © 1999 Wiley-Liss, Inc., A Wiley Company. Published by Elsevier Inc. All rights reserved.